Holen Sie sich die Stockscreener-App
103.80
1.42%
1.45
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$102.35
Offen:
$102
24-Stunden-Volumen:
129.30K
Relative Volume:
1.09
Marktkapitalisierung:
$2.00B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
41.35
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
+3.60%
1M Leistung:
-5.11%
6M Leistung:
-14.20%
1J Leistung:
+28.42%
1-Tages-Spanne:
$101.67
$103.98
1-Wochen-Bereich:
$98.89
$104.01
52-Wochen-Spanne:
$77.42
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
103.80 | 1.93B | 152.42M | 45.24M | 6.97M | 2.51 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017LGND - ACCESS Newswire
BNP Paribas Financial Markets Cuts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Lazard Asset Management LLC Sells 1,507 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Bank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Executives At Ligand Pharmaceuticals Show Confidence With Major Stock Buys - Finimize
Jane Street Group LLC Sells 1,083 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ameriprise Financial Inc. Raises Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 - TradingView
The Manufacturers Life Insurance Company Buys 779 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Executives Increase Holdings - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.com - Defense World
LGND: 1Q:25 Results - MSN
Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Oppenheimer Maintains Rating and Raises Price Target for LGND | - GuruFocus
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript - Insider Monkey
Oppenheimer Maintains Rating and Raises Price Target for LGND | LGND Stock News - GuruFocus
Oppenheimer Raises Price Target for Ligand (LGND) to $145 | LGND Stock News - GuruFocus
Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating - marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highligh - GuruFocus
Earnings call transcript: Ligand Pharmaceuticals beats Q1 2025 expectations - Investing.com
Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth - TipRanks
Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Ligand: Q1 Earnings Snapshot - Huron Daily Tribune
Earnings call transcript: Ligand Pharmaceuticals beats Q1 2025 expectations By Investing.com - Investing.com UK
Ligand Pharmaceuticals Q1 Core Adjusted Earnings, Revenue Increase; Shares Up Pre-Bell - marketscreener.com
Ligand (LGND) Upholds 2025 Financial Guidance | LGND Stock News - GuruFocus
Ligand Pharmaceuticals Reports Q1 Revenue of $45.3M, Beating Estimates; EPS Falls Short with $2.21 Loss - GuruFocus
Ligand (LGND) Exceeds Revenue Expectations with Strategic Moves - GuruFocus
Ligand (LGND) Exceeds Revenue Expectations with Strategic Moves | LGND Stock News - GuruFocus
Ligand Reports First Quarter 2025 Financial Results - GlobeNewswire
Earnings Flash (LGND) Ligand Pharmaceuticals Reports Q1 Adjusted EPS $1.33, vs. FactSet Est of $1.21 - marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals Posts Q1 Revenue $45.3M, vs. FactSet Est of $38.7M - marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Mariner LLC Purchases Shares of 2,574 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Deal Watch: Lilly Looks To Creyon For Oligonucleotides - insights.citeline.com
Ligand to Participate in May Investor Conferences - Stock Titan
Ligand Pharmaceuticals (LGND) Projected to Post Earnings on Thursday - Defense World
Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount? - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Wells Fargo & Company MN - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Sterling Capital Management LLC Has $59,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - American Banking and Market News
Ligand Q1 2025 Earnings Coming May 8: Key Financial Results and Business Updates Expected Pre-Market - Stock Titan
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 - Yahoo Finance
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):